| Literature DB >> 35399833 |
Yangfeng Chi1, Shuang Liu1, Xinye Wu1, Bingbing Zhu1, Hao Wang1, Yongping Liang1, Yunman Wang1.
Abstract
To investigate the effects and mechanisms of resveratrol on glucolipid metabolism in diabetic humans. In this paper, we introduced the knowledge discovery theory into the data processing of the factors related to the pathogenesis of type 2 diabetes for the first time, and identified valid, potentially useful, and understandable pathogenesis patterns from a large amount of measured data. A data mining C4.5 algorithm was used to classify 17072 validated cross-sectional health survey data from the whole population according to the characteristics of type ρ diabetes data. A human model of diabetes mellitus was prepared by high sugar and high fat diet plus low dose streptozotocin (STZ, 35 mg/kg) and randomly grouped into four groups: the normal control group, the model group, the resveratrol group, and the pioglitazone group. 8 animals in each group were treated with the corresponding drugs for 8 weeks. Hepatic steatosis and damage were significantly reduced compared with the model group as observed by HE staining. Resveratrol has obvious effects on regulating glucolipid metabolism, and its mechanism of action is associated with its ability to increase the antioxidant activity of the body, activate the Akt signaling pathway, and improve liver pathological damage.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35399833 PMCID: PMC8989601 DOI: 10.1155/2022/9705144
Source DB: PubMed Journal: J Healthc Eng ISSN: 2040-2295 Impact factor: 2.682
Comparison of glycolipid metabolic indexes in each group after drug administration and treatment (, n = 8).
| Group | FBG | TC | TG | LDL-C | HDL-C |
|---|---|---|---|---|---|
| Normal group | 4.52 ± 0.44 | 1.32 ± 0.19 | 0.73 ± 0.25 | 0.27 ± 0.13 | 0.59 ± 0.04 |
| Model group | 24.6 ± 2.31 | 12.1 ± 0.68 | 3.48 ± 0.43 | 7.13 ± 3.65 | 0.54 ± 0.2 |
| Resveratrol group | 14.3 ± 3.4 | 2.71 ± 0.41 | 1.08 ± 0.31 | 0.75 ±.33 | 0.81 ± 0.12 |
| Pioglitazone group | 13.6 ± 3.01 | 2.42 ± 0.52 | 0.92 ± 0.49 | 0.69 ± 0.15 | 0.91 ±.13 |
Figure 1Effect of liver glycogen content in liver tissue.
Figure 2Effect of resveratrol on SOD activity and MDA content in diabetic human serum.
Figure 3Effect of resveratrol on the phosphorylation level of Akt in diabetic human liver.
Figure 4Effect of resveratrol on GSK-3β activity in diabetic humans.
Figure 5Effect of resveratrol on diabetic human glucose kinase (GCK) protein expression.
Figure 6HE staining of human liver tissue in each group.
Figure 7Clustering subcases of different methods.
Figure 8Recognition efficiency.